drugset / Trial / NCT00967629

Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy

NCT00967629

Phase 1 Completed 20 enrolled Icahn School of Medicine at Mount Sinai
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine whether oral sevelamer carbonate binds advanced glycation end products (AGEs) in the gastrointestinal (GI) tract of patients with diabetic nephropathy leading to decrease body AGE load and therefore decreases the inflammation and oxidative stress in these patients.

Timeline

Start
2009-06
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcium carbonate Other / unclassified 1250 mg
Subject sevelamer Other / unclassified 1600 mg Oral